reviewed april 2026|next review october 2026|88 physicians psi has verified|2 published studies
Glucagon
Glucagon is a 29-amino acid pancreatic hormone FDA-approved as an emergency rescue medication for severe hypoglycemia (Baqsimi, Gvoke, GlucaGen), and the glucagon receptor is now a key component of next-generation obesity drug design.
Evidence landscape: 2 published studies
2 published items indexed for this slug (search-term artifact). The broader glucagon literature exceeds 64,000 studies. A foundational metabolic hormone with decades of clinical use as an emergency medication.
- 2 Animal
FDA-approved in multiple formulations: Baqsimi (nasal spray), Gvoke (autoinjector), GlucaGen (reconstitution kit) for emergency treatment of severe hypoglycemia.
Decades of clinical use for hypoglycemia rescue. The glucagon receptor is the third target in retatrutide (Phase II: 24.2% weight loss) and the second in survodutide (Phase II: 18.7% weight loss).
Counter-regulatory hormone to insulin. The most fundamental metabolic axis in human physiology. Active role in next-generation metabolic drug design beyond single-receptor GLP-1 agonists.
PSI Assessment
Insulin lowers blood sugar. Glucagon raises it. These two pancreatic hormones form the most fundamental metabolic axis in human physiology. Glucagon is FDA-approved as an emergency rescue medication for severe hypoglycemia, available as a nasal spray (Baqsimi), autoinjector (Gvoke), and reconstitution kit (GlucaGen). Beyond the emergency indication, the glucagon receptor is now at the center of next-generation obesity drug design: it is the third receptor in retatrutide's triple mechanism and the second receptor in survodutide's dual mechanism, adding energy expenditure and liver fat oxidation that GLP-1 alone does not provide.
The counter-regulatory hormone to insulin. FDA-approved for hypoglycemia rescue. Now at the center of next-generation obesity drug design.
The mechanism is glucagon receptor activation on hepatocytes. In the emergency setting, this triggers glycogenolysis and gluconeogenesis, rapidly raising blood glucose. In the obesity drug context, the same receptor drives hepatic lipid oxidation, ketogenesis, and thermogenesis, the metabolic pathways that increase energy expenditure and reduce liver fat. The reason glucagon is not used alone for weight loss is that it raises blood sugar. In multi-agonist drugs, the GLP-1 component counterbalances this effect while the glucagon component adds the fat-burning mechanism.
What the evidence supports
Glucagon physiology is foundational endocrinology established over decades of research. FDA-approved for severe hypoglycemia in multiple formulations (Baqsimi nasal spray, Gvoke autoinjector, GlucaGen reconstitution kit). Glucagon receptor agonism produces weight loss and liver fat reduction when combined with GLP-1 in multi-agonist drugs (retatrutide Phase II: 24.2% weight loss; survodutide Phase II: 18.7%).
What is not yet established
Optimal glucagon receptor activation ratio in multi-agonist drugs. Long-term safety of chronic glucagon receptor agonism in obesity treatment. Whether the glucagon component in combination drugs provides clinically meaningful benefit beyond what GLP-1 alone achieves. Phase III data for both retatrutide and survodutide.
Research Evidence
The findings below cover the established emergency indication and the emerging role in metabolic drug design.
Evidence by condition
Evidence dimensions across glucagon indications. Hypoglycemia rescue has the deepest evidence with FDA approval. Metabolic drug design is supported by Phase II multi-agonist data. Type 2 diabetes physiology is foundational endocrinology.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Severe Hypoglycemia | ||||
| Metabolic Drug Design | ||||
| Type 2 Diabetes Physiology |
Glucagon is standard of care for emergency treatment of severe hypoglycemia, with multiple modern formulations eliminating the need for reconstitution. Baqsimi (nasal spray) and Gvoke (autoinjector) allow non-medical personnel to administer in emergencies.
Severe hypoglycemia is a life-threatening complication of insulin therapy. Older glucagon formulations required mixing, which was error-prone during emergencies. The nasal and autoinjector formulations have substantially improved usability.
Glucagon receptor agonism is a key pharmacological component in next-generation obesity drugs. Retatrutide (GLP-1/GIP/glucagon triple agonist, Phase II: up to 24.2% weight loss) and survodutide (GLP-1/glucagon dual agonist, Phase II: 18.7% weight loss) leverage glucagon's ability to increase hepatic lipid oxidation and energy expenditure.
The glucagon component specifically targets liver fat and thermogenesis, pathways that GLP-1 alone does not fully engage. The GLP-1 component counterbalances glucagon's glucose-raising effect, creating a metabolic combination that exceeds what either pathway achieves alone.
Glucagon dysregulation is central to type 2 diabetes physiology. Inappropriate glucagon secretion from alpha cells contributes to fasting hyperglycemia, and restoring normal glucagon regulation is a therapeutic target.
Understanding glucagon's dual role (beneficial in hypoglycemia rescue, pathological when dysregulated in diabetes) is essential context for the metabolic drug design discussion.
0 Human|2 Animal|0 Reviews
View all 2 indexed studiesHow Glucagon Works
Glucagon is a 29-amino acid peptide hormone produced by pancreatic alpha cells. It binds the glucagon receptor (GCGR), a class B G protein-coupled receptor, activating hepatic glycogenolysis, gluconeogenesis, lipid oxidation, and thermogenesis.
Insulin lowers blood sugar. Glucagon raises it. They are opposite signals from the pancreas. When blood sugar drops too low, glucagon tells the liver to release stored glucose. In the obesity drug context, glucagon also tells the liver to burn fat and increases the body's overall calorie burn.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Glucagon is a 29-amino acid peptide from pancreatic alpha cells. It binds the glucagon receptor (GCGR) on hepatocytes, activating glycogenolysis and gluconeogenesis. It also promotes hepatic lipid oxidation, ketogenesis, and thermogenesis. It is the counter-regulatory hormone to insulin.
What is Glucagon being studied for?
Researchers are studying Glucagon across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Glucagon overall. This means a compound can have human studies for one condition but only animal data for another.
Severe Hypoglycemia
·FDA ApprovedFDA-approved emergency treatment for dangerously low blood sugar. Multiple formulations available including nasal spray (Baqsimi), autoinjector (Gvoke), and reconstitution kits (GlucaGen) enabling non-medical personnel to administer.
Limitations: Effect is temporary; underlying cause of hypoglycemia must be addressed. Reconstitution kits require mixing under stressful conditions. Proper storage is required.
Metabolic Drug Design
·Human TrialsGlucagon receptor agonism is a key component in next-generation obesity drugs. Retatrutide (triple agonist) and survodutide (dual agonist) leverage glucagon to increase energy expenditure and reduce liver fat beyond what GLP-1 alone provides.
Limitations: Optimal glucagon receptor activation ratio in multi-agonist drugs is still being determined. Phase III data needed for both retatrutide and survodutide. Whether the glucagon component provides clinically meaningful added benefit is the key open question.
Type 2 Diabetes Physiology
·FDA ApprovedGlucagon dysregulation is central to type 2 diabetes. Elevated glucagon contributes to fasting hyperglycemia through excessive hepatic glucose output. Understanding glucagon is essential to understanding diabetes pathophysiology.
Limitations: Targeting glucagon directly for diabetes treatment is complex because suppression could cause hypoglycemia. The therapeutic opportunity lies in combination approaches.
Safety and Regulatory Status
FDA Status: FDA-approved for emergency treatment of severe hypoglycemia: Baqsimi (nasal spray), Gvoke (autoinjector), GlucaGen (reconstitution kit).
Prescription status: Prescription-only in the United States. Emergency formulations should be readily accessible to patients on insulin therapy.
Class context: Naturally occurring counter-regulatory hormone. Glucagon receptor agonism in newer obesity drugs is combined with GLP-1 to counterbalance the glucose-raising effect.
Common side effects include nausea and vomiting. Emergency formulations are standard of care for severe hypoglycemia with well-characterized safety from decades of use. The glucagon receptor agonism in newer obesity drugs (retatrutide, survodutide) is being monitored for glycemic effects, but the GLP-1 component counterbalances glucagon's glucose-raising activity.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Glucagon discussion.
Comparison and Related Research
Glucagon is most often discussed in the context of insulin (its counter-regulatory partner) and the multi-agonist obesity drugs that include glucagon receptor activation.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Randomized crossover trial testing intranasal glucagon powder against traditional intramuscular injection for treating insulin-induced low blood sugar. The nasal formulation was noninferior to injection, raising blood glucose to safe levels without requiring a needle - a significant practical advance for emergency treatment.Rickels MR et al., 2016 in Diabetes Care. View on PubMed
- 2.Usability study of a ready-to-use glucagon autoinjector (Gvoke) in simulated hypoglycemia emergencies. Caregivers successfully administered the autoinjector significantly faster and with fewer errors than the traditional reconstitution kit, addressing a long-standing barrier to emergency glucagon use.Valentine V et al., 2019 in Diabetes Technol Ther. View on PubMed
- 3.Preclinical study that designed a single molecule activating both glucagon and GLP-1 receptors. The dual-action compound eliminated obesity in mice more effectively than either pathway alone, establishing the scientific rationale for glucagon-containing multi-agonist obesity drugs now in clinical development.Day JW et al., 2009 in Nat Chem Biol. View on PubMed
- 4.Comprehensive review reexamining glucagon's role beyond simply raising blood sugar. Covered emerging evidence that glucagon influences energy expenditure, fat metabolism, and appetite - findings that reshaped scientific understanding of this hormone and its therapeutic potential.Habegger KM et al., 2010 in Nat Rev Endocrinol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.